ACCESS Newswire
30 Jun 2020, 18:08 GMT+10
SEATTLE, WA / ACCESSWIRE / June 29, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, announced today that it has collected in full the $750,000 placed into an escrow account for working capital adjustments. This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY®, to Medexus Pharmaceuticals.
The sale transaction, completed in February 2020, included an upfront payment to Aptevo of $30 million. In addition, Aptevo is eligible to receive potential milestone payments totaling up to $11 million from Medexus related to the certain regulatory and commercial activities. Also, for up to fifteen years, Aptevo will receive deferred payments on future U.S. and Canadian net sales of IXINITY calculated at a low to mid-single digit percentage of net sales.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603 were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo's outlook, financial performance or financial condition, estimated cash burn, Aptevo's technology and related pipeline, collaboration and partnership opportunities, milestones, and any other statements containing the words 'believes,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will' and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 25, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement.
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
+1 206-859-6628
[email protected]
SOURCE: Aptevo Therapeutics
Get a daily dose of Atlanta Leader news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Atlanta Leader.
More InformationKATHMANDU, Nepal: An Indian climber and a Filipino climber were the first to die on Mount Everest during the current climbing season...
MOSCOW, Russia: Russia has sentenced a 33-year-old Australian man to 13 years in a high-security prison for fighting with Ukrainian...
ALMATY, Tajikistan: Tajikistan has officially removed criminal liability for liking social media posts that the government deems extremist,...
SACRAMENTO, California: California Governor Gavin Newsom has proposed cutting back a free healthcare program for low-income undocumented...
DETROIT, Michigan: The FBI has arrested a 19-year-old man from Michigan, Ammar Abdulmajid-Mohamed Said, for allegedly planning a mass...
WASHINGTON, D.C.: Parts of the U.S. and Canada may not have enough electricity this summer if hot weather causes more people to use...
STOCKHOLM, Sweden: Apple has blocked access to the popular video game Fortnite on iPhones in the United States and through Epic Games'...
NEW YORK, New York - U.S. stocks struggled on Monday as a further downgrading of U.S. debt by Moody's sent the dollar sliding and Treasury...
PARIS, France: Richemont, the owner of luxury brands Cartier and Van Cleef & Arpels, posted a stronger-than-expected seven percent...
TOKYO, Japan: Japan's economy contracted for the first time in a year, shrinking at a faster pace than expected in the first quarter...
WASHINGTON, D.C.: Parts of the U.S. and Canada may not have enough electricity this summer if hot weather causes more people to use...
CORAOPOLIS, Pennsylvania: Dick's Sporting Goods is set to acquire Foot Locker in a US$2.4 billion deal, marking the second major footwear...